Physician profile
Stephen Rohrer
NPI 1538611975
$14,580.22
in general payments reported to CMS, 2019-2025
30 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,310 · 2022: $8,358 · 2023: $1,972 · 2024: $543 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $10,872.33 | 2021-2024 | Nuzyra |
| Organogenesis INC. | $597.73 | 2021-2025 | Simplimax, Nushield, Via Matrix |
| Medtronic, INC. | $388.22 | 2021-2025 | Simplera Sensor, Minimed 780g |
| Novo Nordisk INC | $272.32 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Smith+Nephew, INC. | $264.56 | 2021-2025 | Stravix Pl, Collagenase Santyl |
| Abbvie INC. | $263.10 | 2021-2025 | |
| Glaxosmithkline, LLC. | $241.56 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $236.66 | 2023-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $232.57 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $149.74 | 2025 | Cardiomems |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.57 | 2025 | Caplyta |
| Triad Life Sciences INC. | $106.67 | 2022 | |
| Lilly USA, LLC | $104.14 | 2022 | |
| Exact Sciences Corporation | $100.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medline Industries LP | $97.24 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.72 | 2023-2024 | Jardiance |
| Mylan Specialty L.P. | $51.19 | 2023 | Yupelri |
| Sumitomo Pharma America, INC. | $50.57 | 2023-2024 | Gemtesa |
| Reprise Biomedical, INC. | $50.31 | 2025 | Miro3d, Miro 3d |
| Phathom Pharmaceuticals, INC. | $45.72 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $44.76 | 2023-2024 | |
| Cvrx, INC. | $42.88 | 2024-2025 | Barostim Neo System |
| Xeris Pharmaceuticals, INC. | $35.79 | 2024-2025 | Gvoke Hypopen |
| Mannkind Corporation | $24.81 | 2025 | |
| Lundbeck LLC | $19.79 | 2025 | Rexulti |
| Convatec INC. | $16.42 | 2022 | |
| Nabriva Therapeutics, Plc | $15.96 | 2022 | |
| Bioventus LLC | $15.05 | 2024 | Durolane |
| Pfizer INC. | $14.59 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.50 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rohrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.